Feb 28, 2025 18:00
ARTV - Artiva Biotherapeutics, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 2.87 0.14 (4.88%) | --- | --- | --- | 0.0 (0.0%) | 0.14 (4.81%) | 0.0 (0.0%) | 0.0 (0.0%) |
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Market Period:
AfterHours
Earnings & Ratios
- Basic EPS:
- -0.87
- Diluted EPS:
- -0.87
- Basic P/E:
- -3.4598
- Diluted P/E:
- -3.4598
- RSI(14) 1m:
- 0.0
- VWAP:
- 3.01
- RVol:
- 0.1951
Events
| Period | Kind | Movement | Occurred At |
|---|